Gastroenterology
Volume 137, Issue 6 , Pages 1986-1994, December 2009

Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial

  • Mitchell L. Shiffman

      Affiliations

    • Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia
    • Corresponding Author InformationReprint requests Address requests for reprints to: Mitchell L. Shiffman, MD, Hepatology Section, VCU Health System, Box 980341, Richmond, Virginia 23298. fax: (804) 828-4945
    • ,
  • Chihiro Morishima

      Affiliations

    • Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, Washington
    • ,
  • Jules L. Dienstag

      Affiliations

    • Gastrointestinal Unit (Medical Services), Massachusetts General Hospital and the Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • Karen L. Lindsay

      Affiliations

    • Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California
    • ,
  • John C. Hoefs

      Affiliations

    • Division of Gastroenterology, University of California-Irvine, Irvine, California
    • ,
  • William M. Lee

      Affiliations

    • Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • Elizabeth C. Wright

      Affiliations

    • Office of the director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    • ,
  • Deepa Naishadham

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts
    • ,
  • Gregory T. Everson

      Affiliations

    • Section of Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
    • ,
  • Anna S. Lok

      Affiliations

    • Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan
    • ,
  • Adrian M. Di Bisceglie

      Affiliations

    • Division of Gastroenterology and Hepatology, St. Louis University School of Medicine, St. Louis, Missouri
    • ,
  • Herbert L. Bonkovsky

      Affiliations

    • Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut
    • Department of Molecular and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut
    • The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, Connecticut
    • ,
  • Marc G. Ghany

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    • ,
  • HALT-C Trial Group

Received 15 April 2009; accepted 31 August 2009. published online 11 September 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This article has an accompanying continuing medical education activity on page 2159. Learning Objective: Upon completion of reading this article, successful learners will be able to determine the role of peginterferon alfa-2b maintenance therapy on the management of patients with chronic HCV and advanced fibrosis.

 Conflicts of interest The authors disclose the following: M.L. Shiffman, G.T. Everson, A.S. Lok, and A.M. Di Bisceglie are consultants for Hoffmann-La Roche, Inc. M.L. Shiffman, J.C. Hoefs, G.T. Everson, and A.M. Di Bisceglie are on the speaker's bureau of Hoffmann-La Roche, Inc. M.L. Shiffman, W.M. Lee, G.T. Everson, A.M. Di Bisceglie, and H.L. Bonkovsky receive research support from Hoffmann-La Roche, Inc. K.L. Lindsay was a consultant and received research support during this study and is now an employee of Tibotec (a subsidiary of Johnson and Johnson), Yardsley, NJ. The remaining authors disclose no conflicts.

 Funding Supported by the National Institute of Diabetes and Digestive and Kidney Diseases (contract numbers listed above), the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute, the National Center for Minority Health and Health Disparities, and the General Clinical Research Center and Clinical and Translational Science Center grants from the National Center for Research Resources, and National Institutes of Health (grant numbers are listed above). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Additional funding to conduct this study was supplied by Hoffmann-La Roche, Inc, through a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health.

PII: S0016-5085(09)01561-3

doi:10.1053/j.gastro.2009.08.067

Refers to erratum:

  • Correction , 08 February 2010

    Gastroenterology March 2010 (Vol. 138, Issue 3, Page 1215)

Gastroenterology
Volume 137, Issue 6 , Pages 1986-1994, December 2009

Article Tools

* Image Usage & Resolution